Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma

Abstract Background The efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy have been presented and evaluated in previously published TD-NICE study. However, the long-term impacts of patients who received tislelizumab plus chemotherapy followed by surgery were not o...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Yajie Mao, Zhiyuan Gao, Yichen Sun, Changjian Shao, Hongtao Duan, Xiaolong Yan
Format: Article
Language:English
Published: BMC 2025-08-01
Subjects:
Esophageal cancer
Neoadjuvant chemoimmunotherapy
Survival analysis
Online Access:https://doi.org/10.1186/s12885-025-14686-9

Internet

https://doi.org/10.1186/s12885-025-14686-9

Similar Items